CA2339913A1 - Pharmaceutical formulations and method for making - Google Patents
Pharmaceutical formulations and method for making Download PDFInfo
- Publication number
- CA2339913A1 CA2339913A1 CA002339913A CA2339913A CA2339913A1 CA 2339913 A1 CA2339913 A1 CA 2339913A1 CA 002339913 A CA002339913 A CA 002339913A CA 2339913 A CA2339913 A CA 2339913A CA 2339913 A1 CA2339913 A1 CA 2339913A1
- Authority
- CA
- Canada
- Prior art keywords
- formulation
- making
- pharmaceutical formulations
- oral
- pelletizing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 239000004480 active ingredient Substances 0.000 abstract 2
- 238000009472 formulation Methods 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 229930006000 Sucrose Natural products 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 235000014113 dietary fatty acids Nutrition 0.000 abstract 1
- 239000002552 dosage form Substances 0.000 abstract 1
- 229930195729 fatty acid Natural products 0.000 abstract 1
- 239000000194 fatty acid Substances 0.000 abstract 1
- 150000004665 fatty acids Chemical class 0.000 abstract 1
- 239000008187 granular material Substances 0.000 abstract 1
- 239000000155 melt Substances 0.000 abstract 1
- 230000008018 melting Effects 0.000 abstract 1
- 238000002844 melting Methods 0.000 abstract 1
- 239000008203 oral pharmaceutical composition Substances 0.000 abstract 1
- 239000008188 pellet Substances 0.000 abstract 1
- 238000005453 pelletization Methods 0.000 abstract 1
- 239000005720 sucrose Substances 0.000 abstract 1
- -1 sucrose ester Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Obesity (AREA)
- Biochemistry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Otolaryngology (AREA)
- Anesthesiology (AREA)
- Biophysics (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
Abstract
The invention relates to an oral pharmaceutical formulation with variably adjustable release rate, which comprises one or more active ingredients, and one or more sucrose ester of a fatty acid as the sole release-controlling agent for said active ingredient wherein when the dosage form is a granule or a pellet, the formulation is made by melting the oral formulation, and granulating or pelletizing the melt.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10010509.2 | 2000-03-08 | ||
DE2000110509 DE10010509A1 (en) | 2000-03-08 | 2000-03-08 | Oral pharmaceutical formulations with controllable release characteristics, e.g. rapid or delayed release, contain sucrose fatty acid ester as drug release controlling agent |
US18796200P | 2000-03-09 | 2000-03-09 | |
US60/187,992 | 2000-03-09 |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2339913A1 true CA2339913A1 (en) | 2001-09-08 |
CA2339913C CA2339913C (en) | 2009-02-24 |
Family
ID=26004678
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002339913A Expired - Fee Related CA2339913C (en) | 2000-03-08 | 2001-03-07 | Pharmaceutical formulations and method for making |
Country Status (23)
Country | Link |
---|---|
EP (1) | EP1267828B1 (en) |
JP (1) | JP2003528829A (en) |
KR (1) | KR20020083171A (en) |
CN (1) | CN1212831C (en) |
AT (1) | ATE334659T1 (en) |
AU (1) | AU2001250365A1 (en) |
BG (1) | BG107064A (en) |
BR (1) | BR0109036A (en) |
CA (1) | CA2339913C (en) |
CZ (1) | CZ20023009A3 (en) |
DE (1) | DE50110617D1 (en) |
EA (1) | EA200200951A1 (en) |
EE (1) | EE200200504A (en) |
GE (1) | GEP20053455B (en) |
HK (1) | HK1054697A1 (en) |
HR (1) | HRP20020804B1 (en) |
HU (1) | HUP0204513A3 (en) |
IS (1) | IS6511A (en) |
NO (1) | NO20024237L (en) |
NZ (1) | NZ521215A (en) |
PL (1) | PL202935B1 (en) |
SK (1) | SK13252002A3 (en) |
WO (1) | WO2001066081A2 (en) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1490031A1 (en) * | 2002-03-07 | 2004-12-29 | Vectura Limited | Fast melt multiparticulate formulations for oral delivery |
CA2509259A1 (en) * | 2003-01-23 | 2004-08-05 | Amorepacific Corporation | Sustained-release preparations and method for producing the same |
DE10341264A1 (en) * | 2003-09-04 | 2005-03-24 | Grünenthal GmbH | Melt-formulated, multiparticulate oral dosage form |
JP2007533733A (en) * | 2004-04-22 | 2007-11-22 | モル リサーチ アプリケーションズ リミテッド | How to control food intake |
AU2009270768A1 (en) * | 2008-07-18 | 2010-01-21 | Valeant Pharmaceuticals International | Modified release formulation and methods of use |
US8715715B2 (en) * | 2008-11-03 | 2014-05-06 | Nal Pharmaceuticals Ltd. | Dosage form for insertion into the mouth |
DE102009013613A1 (en) | 2009-03-17 | 2010-09-23 | Ratiopharm Gmbh | Dry processing of retigabine |
DE102009013612A1 (en) | 2009-03-17 | 2010-09-23 | Ratiopharm Gmbh | Retigabine tablets, preferably with modified release |
DE102009013611A1 (en) | 2009-03-17 | 2010-09-23 | Ratiopharm Gmbh | Solid retigabine in non-crystalline form |
BR112012018173A2 (en) * | 2010-01-20 | 2017-08-29 | Valeant Pharmaceuticals Int | "MODIFIED RELEASE FORMULATION AND METHOD OF USE" |
EP2729176A1 (en) | 2011-07-05 | 2014-05-14 | Contera Pharma APS | The use of serotonin receptor agonists for treatment of movement disorders |
US9616025B2 (en) * | 2013-10-29 | 2017-04-11 | Echo Pharmaceuticals B.V. | Compressed tablet containing Δ9-tetrahydrocannabinol, method for its manufacture and use of such tablet in oral treatment |
US11331268B2 (en) * | 2016-11-18 | 2022-05-17 | The University Of Western Australia | Taste masking product |
CN107441055A (en) * | 2017-08-03 | 2017-12-08 | 山东则正医药技术有限公司 | A kind of preparation method of controlled release drug |
CN108853044B (en) * | 2018-07-06 | 2020-11-06 | 郑州明泽医药科技有限公司 | Nifedipine sustained release tablet and preparation method thereof |
CN109679147B (en) * | 2018-12-28 | 2021-05-11 | 广西科技师范学院 | Plant microfine fiber sucrose fatty acid ester enrichment and preparation method thereof |
GB201904767D0 (en) | 2019-04-04 | 2019-05-22 | Orexo Ab | New pharmaceutical compositions |
WO2021145625A1 (en) * | 2020-01-13 | 2021-07-22 | 한국유나이티드제약 주식회사 | Pharmaceutical composition comprising r-thioctic acid or pharmaceutically acceptable salt thereof and enteric coating base material |
CN111513192A (en) * | 2020-05-19 | 2020-08-11 | 北京中联华康科技有限公司 | Esterified cysteamine hydrochloride stable powder and preparation method and application thereof |
CN114983964B (en) * | 2022-06-24 | 2024-05-03 | 广东恒健制药有限公司 | Cefdinir granule and preparation method thereof |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS63101320A (en) * | 1986-10-17 | 1988-05-06 | Dainippon Pharmaceut Co Ltd | Calcium valproate preparation |
JPH07267850A (en) * | 1994-03-28 | 1995-10-17 | Eisai Co Ltd | Medicine composition prevented in unpleasant taste and method for producing the same |
JP4078567B2 (en) * | 1997-04-25 | 2008-04-23 | 東和薬品株式会社 | Sustained release microcapsules and production method thereof |
JP4299384B2 (en) * | 1997-07-15 | 2009-07-22 | 富山化学工業株式会社 | Anti-elution delay fine granules |
HU230889B1 (en) * | 1998-03-26 | 2018-12-28 | Astellas Pharma Inc. | Sustained release preparations |
DE19840152A1 (en) * | 1998-09-03 | 2000-03-09 | Dresden Arzneimittel | Pharmaceutical compositions containing calcium valproate with a delayed release of active substance, process for their preparation and their use |
DE19916383A1 (en) * | 1999-03-31 | 2000-10-05 | Schering Ag | Pharmaceutical composition with an extrusion |
-
2001
- 2001-03-06 CN CNB018061893A patent/CN1212831C/en not_active Expired - Fee Related
- 2001-03-06 NZ NZ521215A patent/NZ521215A/en unknown
- 2001-03-06 DE DE50110617T patent/DE50110617D1/en not_active Revoked
- 2001-03-06 PL PL362547A patent/PL202935B1/en not_active IP Right Cessation
- 2001-03-06 JP JP2001564734A patent/JP2003528829A/en active Pending
- 2001-03-06 EA EA200200951A patent/EA200200951A1/en unknown
- 2001-03-06 BR BR0109036-4A patent/BR0109036A/en not_active Application Discontinuation
- 2001-03-06 HU HU0204513A patent/HUP0204513A3/en unknown
- 2001-03-06 CZ CZ20023009A patent/CZ20023009A3/en unknown
- 2001-03-06 EE EEP200200504A patent/EE200200504A/en unknown
- 2001-03-06 AT AT01923641T patent/ATE334659T1/en not_active IP Right Cessation
- 2001-03-06 SK SK1325-2002A patent/SK13252002A3/en not_active Application Discontinuation
- 2001-03-06 WO PCT/EP2001/002500 patent/WO2001066081A2/en active IP Right Grant
- 2001-03-06 AU AU2001250365A patent/AU2001250365A1/en not_active Abandoned
- 2001-03-06 KR KR1020027011672A patent/KR20020083171A/en not_active Application Discontinuation
- 2001-03-06 EP EP01923641A patent/EP1267828B1/en not_active Revoked
- 2001-03-06 GE GE4946A patent/GEP20053455B/en unknown
- 2001-03-07 CA CA002339913A patent/CA2339913C/en not_active Expired - Fee Related
-
2002
- 2002-08-20 IS IS6511A patent/IS6511A/en unknown
- 2002-09-05 BG BG107064A patent/BG107064A/en unknown
- 2002-09-05 NO NO20024237A patent/NO20024237L/en not_active Application Discontinuation
- 2002-10-07 HR HR20020804A patent/HRP20020804B1/en not_active IP Right Cessation
-
2003
- 2003-09-30 HK HK03107084A patent/HK1054697A1/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
WO2001066081A2 (en) | 2001-09-13 |
WO2001066081A3 (en) | 2002-03-14 |
NO20024237D0 (en) | 2002-09-05 |
PL362547A1 (en) | 2004-11-02 |
AU2001250365A1 (en) | 2001-09-17 |
HRP20020804B1 (en) | 2008-06-30 |
HRP20020804A2 (en) | 2004-12-31 |
HUP0204513A2 (en) | 2003-05-28 |
HK1054697A1 (en) | 2003-12-12 |
EP1267828B1 (en) | 2006-08-02 |
NZ521215A (en) | 2005-04-29 |
SK13252002A3 (en) | 2003-07-01 |
EE200200504A (en) | 2004-02-16 |
NO20024237L (en) | 2002-09-05 |
PL202935B1 (en) | 2009-08-31 |
EP1267828A2 (en) | 2003-01-02 |
EA200200951A1 (en) | 2003-02-27 |
GEP20053455B (en) | 2005-02-25 |
CZ20023009A3 (en) | 2003-06-18 |
CN1418091A (en) | 2003-05-14 |
CN1212831C (en) | 2005-08-03 |
IS6511A (en) | 2002-08-20 |
KR20020083171A (en) | 2002-11-01 |
BR0109036A (en) | 2003-03-18 |
ATE334659T1 (en) | 2006-08-15 |
BG107064A (en) | 2003-04-30 |
JP2003528829A (en) | 2003-09-30 |
HUP0204513A3 (en) | 2004-06-28 |
CA2339913C (en) | 2009-02-24 |
DE50110617D1 (en) | 2006-09-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2339913A1 (en) | Pharmaceutical formulations and method for making | |
CA2377299A1 (en) | Mesalazine controlled release oral pharmaceutical compositions | |
US5405617A (en) | Aliphatic or fatty acid esters as a solventless carrier for pharmaceuticals | |
EP1587497B1 (en) | Method for producing an immediately decomposing oral form of administration which releases active ingredients | |
WO1999017742A3 (en) | Taste masked formulations | |
AU622751B2 (en) | Modified release gemfibrozil composition | |
CA2407072A1 (en) | Taste masking coating composition | |
WO2001078725A3 (en) | Modified release formulations containing a hypnotic agent | |
CA2436287A1 (en) | Fast dissolving tablet | |
NZ334914A (en) | Taste-masked microcapsule compositions and methods of manufacture using a phase seperation-coacervation technique | |
IL111647A (en) | Pharmaceutical compositions comprising microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles and their preparation | |
CA2232450A1 (en) | Oral pharmaceutical composition containing antimicrobial actives and sustained release pantoprazole | |
CA2330480A1 (en) | Controlled release formulation of divalproex sodium | |
CA2158630A1 (en) | Dosage forms containing thioctic acid or solid salts of thioctic acid with improved release and bioavailability | |
AU2915789A (en) | Pharmaceutical compositions | |
WO2003072083A3 (en) | Melt extrusion consisting of salts of active ingredients | |
CA2240281A1 (en) | Modified release oral pharmaceutical composition containing 5-asa and method for the treatment of bowel diseases | |
WO2002056881A8 (en) | Fenofibrate tablets | |
CA2535340A1 (en) | Fast dissolving tablet | |
IL174009A (en) | Melt-formulated, multi-particulate oral dosage form | |
YU64001A (en) | Controlled-release compositions of betahistine | |
CA2397942A1 (en) | Controlled release pharmaceutical composition containing tramadol hydrochloride and method for its preparation | |
YU66902A (en) | Pharmaceutical preparations containing saccharose fatty acid esters for controlling the release of active ingredients |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |